약제 용출형 스텐트 시장 규모, 점유율, 성장률 및 세계 업계 분석, 지역별 인사이트 및 예측(2026-2034년)

Growth Factors of drug eluting stent (DES) Market

The global drug eluting stent (DES) market size was valued at USD 6.94 billion in 2025 and is projected to grow from USD 7.59 billion in 2026 to USD 15.52 billion by 2034, driven by the increasing prevalence of cardiovascular diseases, rising adoption of minimally invasive cardiovascular interventions, and continuous advancements in stent technologies. North America dominated the market with a 30.82% share in 2025, supported by favorable reimbursement policies, advanced healthcare infrastructure, and increasing demand for coronary interventions.

Market Definition and Scope

A drug eluting stent is a semi-rigid, tube-like metallic medical device coated with a therapeutic drug that is gradually released after implantation. The drug helps reduce restenosis and the recurrence of arterial blockages. Modern DES technologies focus on improved flexibility, biocompatibility, delivery systems, and reduced risks of thrombosis. The market covers coronary and peripheral stenting procedures and includes different drugs, scaffold materials, and healthcare end users.

Drug Eluting Stent Market Trends

The development of bioabsorbable polymer-coated drug eluting stents is an important market trend. These stents are designed to improve vessel healing while reducing long-term polymer exposure. Manufacturers are increasingly investing in ultrathin stents, advanced drug formulations, and improved delivery systems to address complex lesions and improve clinical outcomes.

Technological innovation is also encouraging healthcare providers to adopt newer-generation DES products that offer better flexibility, vessel compatibility, and controlled drug release.

Market Growth Factors and Dynamics

Driver - Rising Cardiovascular Disease Burden: The increasing prevalence of coronary artery disease, peripheral arterial disease, diabetes, obesity, smoking, and sedentary lifestyles is creating sustained demand for cardiovascular interventions and drug eluting stents.

Driver - Advanced Stent Technologies: Continuous research and development is leading to bioabsorbable polymers, ultrathin stent designs, improved scaffolds, and advanced delivery systems, supporting broader adoption in complex cardiovascular procedures.

Restraint - Product Recalls: Product recalls associated with deployment issues, device performance, or other safety concerns can affect physician confidence and increase regulatory pressure, limiting market expansion.

Market Opportunity - Minimally Invasive Cardiovascular Treatment: Increasing preference for minimally invasive procedures and the expansion of cardiovascular treatment infrastructure in emerging economies provide opportunities for DES manufacturers.

Challenge - Clinical and Regulatory Requirements: Manufacturers must demonstrate device safety, effectiveness, durability, and clinical performance while meeting stringent regulatory requirements, which can increase development costs and commercialization timelines.

Segmentation Analysis

By Type

Based on indication, the market is divided into coronary stenting and peripheral stenting. Coronary stenting remains the leading segment because of the widespread prevalence of coronary artery disease and the extensive use of DES in percutaneous coronary interventions. The coronary stenting segment accounted for 80.1% of the market in 2025. Peripheral stenting is expected to gain importance as peripheral vascular diseases become more prevalent.

By Drug

The market includes Sirolimus, Paclitaxel, Zotarolimus, Everolimus, and Others. Sirolimus has historically been widely used because of its effectiveness in reducing restenosis, while newer-generation stents increasingly use Zotarolimus and Everolimus because of their clinical performance and improved vessel healing characteristics.

By Scaffold

Scaffolds include cobalt-chromium, platinum-chromium, nitinol, and others. Cobalt-chromium remains a leading material because of its flexibility, biocompatibility, durability, and suitability for modern DES designs.

By End User

Hospitals represent a major end-user segment due to the high volume of coronary intervention procedures and increasing healthcare infrastructure. Specialty clinics and ambulatory surgical centers are also gaining importance as selected cardiovascular procedures increasingly shift toward outpatient settings.

Regional Analysis

North America remains the leading regional market, supported by favorable reimbursement policies, advanced healthcare infrastructure, cardiovascular disease prevalence, and significant research and development activities.

Europe is expected to maintain steady growth through advancements in polymer technology, new product approvals, and increasing adoption of newer-generation DES.

Asia Pacific offers significant growth opportunities due to rising cardiovascular disease prevalence, improving healthcare infrastructure, and increasing adoption of technologically advanced cardiovascular devices. Japan is expected to reach USD 367.7 million in 2025.

Latin America and the Middle East & Africa are expected to expand at moderate rates as healthcare infrastructure and access to advanced cardiovascular interventions continue to improve.

Competitive Landscape and Key Industry Players

The DES market is relatively consolidated, with major companies emphasizing product innovation, clinical research, regulatory approvals, geographic expansion, and strategic investments. Key industry players include Boston Scientific Corporation, Abbott, Medtronic, Biotronik, Terumo Corporation, MicroPort Scientific Corporation, and Sahajanand Medical Technologies.

Key Industry Developments

Recent industry developments have focused on shorter dual antiplatelet therapy options, advanced DES systems for complex lesions, expanded regulatory approvals, and commercialization of newer-generation stents. These developments reflect manufacturers' efforts to improve patient outcomes and broaden the clinical applications of DES technologies.

Future Outlook

The market is expected to benefit from increasing cardiovascular disease prevalence, rising healthcare expenditure, growing demand for minimally invasive interventions, and continued innovation in stent materials and drug-delivery technologies. Bioabsorbable polymers, ultrathin designs, and advanced scaffolds are likely to remain important areas of development through 2034.

Report Coverage

The Drug Eluting Stent market analysis covers market size and market value, segmentation by type, drug, scaffold, and end user, regional developments, market trends, growth drivers, restraints, opportunities, challenges, competitive strategies, key companies, and industry developments. The analysis provides an overview of the factors shaping demand for DES technologies across major healthcare markets.

Conclusion

The Drug Eluting Stent market is positioned for strong expansion, increasing from a market size of USD 6.94 billion in 2025 to USD 7.59 billion in 2026 and USD 15.52 billion by 2034. Rising cardiovascular disease prevalence and continuous innovation in stent design will remain major growth drivers. At the same time, product safety requirements and recalls present challenges for manufacturers. The development of bioabsorbable polymers, advanced scaffolds, and minimally invasive cardiovascular technologies is expected to create significant opportunities and strengthen the market outlook through 2034.

Unit Value (USD billion)

Segmentation By Type

• Coronary Stenting
• Peripheral Stenting

By Scaffold

• Cobalt-Chromium
• Platinum-Chromium
• Nitinol
• Others

By Drug

• Sirolimus
• Paclitaxel
• Zotarolimus
• Everolimus
• Others

By End User

• Hospitals
• Specialty Clinics

By Geography

• North America (the U.S. and Canada)
• Europe (U.K., Germany, France, Italy, Spain, Scandinavia, and the Rest of Europe)
• Asia-Pacific (Japan, China, India, Australia, Southeast Asia, and the Rest of Asia- Pacific)
• Latin America (Brazil, Mexico, and the Rest of Latin America)
• Middle East & Africa (South Africa, GCC and the Rest of Middle East & Africa)

Table of Content

1. Introduction

• 1.1. Research Scope
• 1.2. Market Segmentation
• 1.3. Research Methodology
• 1.4. Definitions and Assumptions

2. Executive Summary

3. Market Dynamics

• 3.1. Market Drivers
• 3.2. Market Restraints
• 3.3. Market Opportunities

4. Key Insights

• 4.1. Prevalence of Cardiovascular Diseases, By Key Regions/ Key Countries, 2025
• 4.2. New Product Launches, By Key Market Players
• 4.3. Key Industry Developments, Such as Mergers & Acquisitions
• 4.4. Pricing Analysis, By Key Brands, Key Players/ Key Regions

5. Global Drug Eluting Stents (DES) Market Analysis, Insights and Forecast, 2021-2034

• 5.1. Key Findings / Summary
• 5.2. Market Analysis, Insights and Forecast - By Type
  • 5.2.1. Coronary Stenting
  • 5.2.2. Peripheral Stenting
• 5.3. Market Analysis, Insights and Forecast - By Scaffold
  • 5.3.1. Cobalt-Chromium
  • 5.3.2. Platinum-Chromium
  • 5.3.3. Nitinol
  • 5.3.4. Others
• 5.4. Market Analysis, Insights and Forecast - By Drug
  • 5.4.1. Sirolimus
  • 5.4.2. Paclitaxel
  • 5.4.3. Zotarolimus
  • 5.4.4. Everolimus
  • 5.4.5. Others
• 5.5. Market Analysis, Insights and Forecast - By End User
  • 5.5.1. Hospitals
  • 5.5.2. Specialty Clinics
• 5.6. Market Analysis, Insights and Forecast - By Region
  • 5.6.1. North America
  • 5.6.2. Europe
  • 5.6.3. Asia Pacific
  • 5.6.4. Latin America
  • 5.6.5. Middle East & Africa

6. North America Drug Eluting Stents (DES) Market Analysis, Insights and Forecast, 2021-2034

• 6.1. Key Findings / Summary
• 6.2. Market Analysis, Insights and Forecast - By Type
  • 6.2.1. Coronary Stenting
  • 6.2.2. Peripheral Stenting
• 6.3. Market Analysis, Insights and Forecast - By Scaffold
  • 6.3.1. Cobalt-Chromium
  • 6.3.2. Platinum-Chromium
  • 6.3.3. Nitinol
  • 6.3.4. Others
• 6.4. Market Analysis, Insights and Forecast - By Drug
  • 6.4.1. Sirolimus
  • 6.4.2. Paclitaxel
  • 6.4.3. Zotarolimus
  • 6.4.4. Everolimus
  • 6.4.5. Others
• 6.5. Market Analysis, Insights and Forecast - By End User
  • 6.5.1. Hospitals
  • 6.5.2. Specialty Clinics
• 6.6. Market Analysis, Insights and Forecast - By Country
  • 6.6.1. U.S.
  • 6.6.2. Canada

7. Europe Drug Eluting Stents (DES) Market Analysis, Insights and Forecast, 2021-2034

• 7.1. Key Findings / Summary
• 7.2. Market Analysis, Insights and Forecast - By Type
  • 7.2.1. Coronary Stenting
  • 7.2.2. Peripheral Stenting
• 7.3. Market Analysis, Insights and Forecast - By Scaffold
  • 7.3.1. Cobalt-Chromium
  • 7.3.2. Platinum-Chromium
  • 7.3.3. Nitinol
  • 7.3.4. Others
• 7.4. Market Analysis, Insights and Forecast - By Drug
  • 7.4.1. Sirolimus
  • 7.4.2. Paclitaxel
  • 7.4.3. Zotarolimus
  • 7.4.4. Everolimus
  • 7.4.5. Others
• 7.5. Market Analysis, Insights and Forecast - By End User
  • 7.5.1. Hospitals
  • 7.5.2. Specialty Clinics
• 7.6. Market Analysis, Insights and Forecast - By Country/ Sub-region
  • 7.6.1. U.K.
  • 7.6.2. Germany
  • 7.6.3. France
  • 7.6.4. Spain
  • 7.6.5. Italy
  • 7.6.6. Scandinavia
  • 7.6.7. Rest of Europe

8. Asia Pacific Drug Eluting Stents (DES) Market Analysis, Insights and Forecast, 2021-2034

• 8.1. Key Findings / Summary
• 8.2. Market Analysis, Insights and Forecast - By Type
  • 8.2.1. Coronary Stenting
  • 8.2.2. Peripheral Stenting
• 8.3. Market Analysis, Insights and Forecast - By Scaffold
  • 8.3.1. Cobalt-Chromium
  • 8.3.2. Platinum-Chromium
  • 8.3.3. Nitinol
  • 8.3.4. Others
• 8.4. Market Analysis, Insights and Forecast - By Drug
  • 8.4.1. Sirolimus
  • 8.4.2. Paclitaxel
  • 8.4.3. Zotarolimus
  • 8.4.4. Everolimus
  • 8.4.5. Others
• 8.5. Market Analysis, Insights and Forecast - By End User
  • 8.5.1. Hospitals
  • 8.5.2. Specialty Clinics
• 8.6. Market Analysis, Insights and Forecast - By Country/ Sub-region
  • 8.6.1. Japan
  • 8.6.2. China
  • 8.6.3. India
  • 8.6.4. Australia
  • 8.6.5. Southeast Asia
  • 8.6.6. Rest of Asia Pacific

9. Latin America Drug Eluting Stents (DES) Market Analysis, Insights and Forecast, 2021-2034

• 9.1. Key Findings / Summary
• 9.2. Market Analysis, Insights and Forecast - By Type
  • 9.2.1. Coronary Stenting
  • 9.2.2. Peripheral Stenting
• 9.3. Market Analysis, Insights and Forecast - By Scaffold
  • 9.3.1. Cobalt-Chromium
  • 9.3.2. Platinum-Chromium
  • 9.3.3. Nitinol
  • 9.3.4. Others
• 9.4. Market Analysis, Insights and Forecast - By Drug
  • 9.4.1. Sirolimus
  • 9.4.2. Paclitaxel
  • 9.4.3. Zotarolimus
  • 9.4.4. Everolimus
  • 9.4.5. Others
• 9.5. Market Analysis, Insights and Forecast - By End User
  • 9.5.1. Hospitals
  • 9.5.2. Specialty Clinics
• 9.6. Market Analysis, Insights and Forecast - By Country/ Sub-region
  • 9.6.1. Brazil
  • 9.6.2. Mexico
  • 9.6.3. Rest of Latin America

10. Middle East & Africa Drug Eluting Stents (DES) Market Analysis, Insights and Forecast, 2021-2034

• 10.1. Key Findings / Summary
• 10.2. Market Analysis, Insights and Forecast - By Type
  • 10.2.1. Coronary Stenting
  • 10.2.2. Peripheral Stenting
• 10.3. Market Analysis, Insights and Forecast - By Scaffold
  • 10.3.1. Cobalt-Chromium
  • 10.3.2. Platinum-Chromium
  • 10.3.3. Nitinol
  • 10.3.4. Others
• 10.4. Market Analysis, Insights and Forecast - By Drug
  • 10.4.1. Sirolimus
  • 10.4.2. Paclitaxel
  • 10.4.3. Zotarolimus
  • 10.4.4. Everolimus
  • 10.4.5. Others
• 10.5. Market Analysis, Insights and Forecast - By End User
  • 10.5.1. Hospitals
  • 10.5.2. Specialty Clinics
• 10.6. Market Analysis, Insights and Forecast - By Country/ Sub-region
  • 10.6.1. GCC Countries
  • 10.6.2. South Africa
  • 10.6.3. Rest of Middle East & Africa

11. Competitive Analysis

• 11.1. Key Industry Developments
• 11.2. Global Market Share Analysis (2025)
• 11.3. Company Profiles
  • 11.3.1. Boston Scientific Corporation
    • 11.3.1.1. Overview,
    • 11.3.1.2. Products,
    • 11.3.1.3. SWOT,
    • 11.3.1.4. Recent Developments,
    • 11.3.1.5. Strategies,
    • 11.3.1.6. Financials (based on availability)
  • 11.3.2. Abbott
    • 11.3.2.1. Overview,
    • 11.3.2.2. Products,
    • 11.3.2.3. SWOT,
    • 11.3.2.4. Recent Developments,
    • 11.3.2.5. Strategies,
    • 11.3.2.6. Financials (based on availability)
  • 11.3.3. Medtronic
    • 11.3.3.1. Overview,
    • 11.3.3.2. Products,
    • 11.3.3.3. SWOT,
    • 11.3.3.4. Recent Developments,
    • 11.3.3.5. Strategies,
    • 11.3.3.6. Financials (based on availability)
  • 11.3.4. Biotronik
    • 11.3.4.1. Overview,
    • 11.3.4.2. Products,
    • 11.3.4.3. SWOT,
    • 11.3.4.4. Recent Developments,
    • 11.3.4.5. Strategies,
    • 11.3.4.6. Financials (based on availability)
  • 11.3.5. Terumo Corporation
    • 11.3.5.1. Overview,
    • 11.3.5.2. Products,
    • 11.3.5.3. SWOT,
    • 11.3.5.4. Recent Developments,
    • 11.3.5.5. Strategies,
    • 11.3.5.6. Financials (based on availability)
  • 11.3.6. MicroPort Scientific Corporation
    • 11.3.6.1. Overview,
    • 11.3.6.2. Products,
    • 11.3.6.3. SWOT,
    • 11.3.6.4. Recent Developments,
    • 11.3.6.5. Strategies,
    • 11.3.6.6. Financials (based on availability)
  • 11.3.7. Other Prominent Players
    • 11.3.7.1. Overview,
    • 11.3.7.2. Products,
    • 11.3.7.3. SWOT,
    • 11.3.7.4. Recent Developments,
    • 11.3.7.5. Strategies,
    • 11.3.7.6. Financials (based on availability)

12. Strategic Recommendations